Clinical trials: Melanoma Stage III
Malignant Melanoma
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery…
- Trial name
- NCT00039000
- Testing
- HSPPC-96 or Oncophage
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 350 people
- Sponsor
- Agenus Inc.
Melanoma Stage III, Melanoma Stage IV
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for…
- Trial name
- INTACT/MeRCI (NCT06284590)
- Testing
- L19IL2, L19TNF, L19IL2/L19TNF
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 162 people
- Sponsor
- Philogen S.p.A.
Melanoma
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
- Trial name
- NCT03002376
- Testing
- REGN2810
- Where
- 8 sites in Netherlands, Serbia and 2 more
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
This is a Phase II/III randomized, controlled, multicenter, open-label study designed to assess the safety, efficacy, and impact on quality of life of PEG Intron (MK-4031) and INTRON® A (MK-2958) and the pharmacokinetics of PEG…
- Trial name
- NCT03552549
- Testing
- PEG-Intron, INTRON A
- Volunteers
- 126 people
- Sponsor
- Merck Sharp & Dohme LLC
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients…
- Trial name
- NCT07581509
- Testing
- Bmab1800, US-Licensed Keytruda
- Where
- Brazil
- Volunteers
- 138 people
- Sponsor
- Biocon Biologics UK PLC
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide…
- Trial name
- NCT05647954
- Testing
- HX008 + TACE, Temozolomide + TACE, Pembrolizumab
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Melanoma
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in…
- Trial name
- NCT00111007
- Testing
- Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 270 people
- Sponsor
- Bayer
Melanoma
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma.
- Trial name
- NCT00272415
- Testing
- INO-1001, temozolomide
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
Malignant Melanoma With Metastasis, Malignant Melanoma
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1…
- Conditions
- Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
- Trial name
- NCT06708455
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Rapa Therapeutics LLC
Melanoma
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
This study will collect real-world data from advanced melanoma diagnosis through most recent visit and data sourced from patient medical records following a 2-part study design consisting of a random sample (Part 1) and an…
- Trial name
- NCT03199846
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Bristol-Myers Squibb
Melanoma Stage IV, Melanoma Stage III
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or…
- Trial name
- BERING (NCT04045691)
- Testing
- Encorafenib, Binimetinib
- Where
- 59 sites in Austria, Germany and 1 more
- Volunteers
- 750 people
- Sponsor
- Pierre Fabre Pharma GmbH
Melanoma
Intralesional PV-10 Chemoablation of Metastatic Melanoma
The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of metastatic melanoma. This study will also include a preliminary assessment of response of treated and untreated lesions by…
- Trial name
- NCT00219843
- Testing
- PV-10 (rose bengal disodium, 10%)
- Where
- 2 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Provectus Pharmaceuticals
Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's white blood cells combined with melanoma antigens may make the body build an immune response to tumor cells.
- Trial name
- NCT00004025
- Testing
- aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Melanoma (Skin Cancer), Melanoma Stage IIIB-IV
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow…
- Conditions
- Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
- Trial name
- NCT06624644
- Testing
- LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide)
- Where
- 9 sites in United States
- Volunteers
- 135 people
- Sponsor
- Linnaeus Therapeutics, Inc.
Melanoma, Melanoma Stage III
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for…
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
- Trial name
- PIVOT-12 (NCT04410445)
- Testing
- Bempegaldesleukin, Nivolumab
- Where
- 212 sites in United States, Australia and 15 more
- Volunteers
- 765 people
- Sponsor
- Nektar Therapeutics
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected).
- Trial name
- NCT03655756
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- TuHURA Biosciences, Inc.
Malignant Melanoma
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria [irRECIST 1.1]…
- Trial name
- CALM (NCT01227551)
- Testing
- Coxsackievirus A21 (CVA21)
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Viralytics
Melanoma
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
This will show if CP-675,206 can be administered safely as an intravenous infusion lasting one hour. CP 675,206 already has been administered to 835 subjects over 1.0 - 7.5 hours.
- Trial name
- NCT00585000
- Testing
- CP-675,206
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of…
- Trial name
- NCT07476326
- Testing
- Bmab1700, Opdivo
- Where
- 46 sites in Brazil, Chile and 8 more
- Volunteers
- 120 people
- Sponsor
- Biocon Biologics UK PLC
Melanoma (Skin), Metastatic Cancer
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00039234
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 19 sites in United States, Canada and 2 more
- Sponsor
- Maxim Pharmaceuticals